Primer

Yatsen Primer

Yatsen Holding Limited (NYSE: YSG) is a Guangzhou-based beauty group founded in 2016 that owns a portfolio of color cosmetics brands (Perfect Diary, Little Ondine, Pink Bear) and clinical/premium skincare brands (Galénic, DR.WU mainland China, Eve Lom). The company sells direct-to-consumer through China's major e-commerce, social and content platforms, with a digitally-native marketing model built around KOLs, IP collaborations and Tmall/Douyin/RedNote/JD storefronts. After three years of revenue declines and large GAAP losses, the business returned to growth in 2025 on the back of higher-margin skincare and reached non-GAAP breakeven for the full year.

Five-Year Price Path

The ADS is down roughly 96% over five years and 53% over the trailing twelve months, with most of the recent decline concentrated in the last six months. Price points are approximate, sampled from public quotes; daily data was not available to this run.

Revenue Mix And Margin Trend

Skincare overtook color cosmetics in FY2025 (53% of revenue) and is the primary driver of the gross-margin expansion from 68% in 2022 to 78% in 2025. Net loss has narrowed sharply as selling-and-marketing leverage improved on a higher revenue base, and the company posted its first full year of non-GAAP profitability in 2025.

Business In One Page

What it sells. Color cosmetics (lip, eye, face) under Perfect Diary, Little Ondine and Pink Bear; clinical/premium skincare under Galénic (acquired from Pierre Fabre in 2020), DR.WU mainland China (acquired 2021), Eve Lom (acquired 2021) and EANTiM (2021). Perfect Diary remains the flagship and one of the leading domestic color cosmetics brands in China by retail sales value.

Customers and geography. Primarily Gen-Z and millennial women in Chinese Tier 1–3 cities. Galénic and Eve Lom also sell internationally. Per the 2024 20-F, 88 offline experience stores supplement the online channel; the bulk of revenue is generated via Tmall, Douyin, JD.com, Pinduoduo, Vipshop, RedNote, Kuaishou and the company's own WeChat (Weixin) Xiaowanzi shop.

Economics. Asset-light DTC model: products are produced mainly through ODM/OEM partners (Cosmax, Intercos, HCP, Axilone, Qiaxing), with one majority-Cosmax minority-Yatsen joint-venture manufacturing/R&D hub in Guangzhou opened in 2023. Gross margin has climbed each year since 2022 as the mix shifts toward higher-priced skincare and as discounting on color cosmetics is tightened. Selling and marketing expense ran at 68% of revenue in Q3 2025 (down from 73% a year earlier) — the dominant cost line and the key swing factor for operating profitability. R&D ran 3.2% of revenue in 2024 with a global "1-3-4-6-20" framework of labs, collaborations (Ruijin Hospital, Sun Yat-sen University, Chinese Academy of Sciences, Lubrizol) and 245 registered patents.

Structure. Cayman Islands holding company with PRC operations conducted through wholly foreign-owned subsidiaries and a VIE (Huizhi Weimei). ADRs represent 20 Class A ordinary shares after the March 2024 ratio change; founder/CEO Jinfeng Huang controls Class B super-voting shares, making Yatsen a "controlled company" under NYSE rules.

What Changed Recently

• Full-year 2025 results (reported 2 Mar 2026): revenue +26.7% to RMB4.30B, skincare +63.5% to ~53% of sales, gross margin 78.2%, GAAP net loss narrowed to RMB92.4M and non-GAAP net income RMB8.4M — first full year of non-GAAP profitability. Cash, restricted cash and short-term investments RMB1.05B. Source: Yatsen FY2025 release via Stock Titan.
• Q1 2026 revenue guidance of RMB958.6M–RMB1.08B implies ~15%+ year-over-year growth and continued top-line momentum, per the company's FY2025 release.
• 2025 Form 20-F filed 29 Apr 2026 with the SEC, confirming continued NYSE listing in good standing. Source: Yatsen Holding Limited press release distributed by PR Newswire / Morningstar.
• Q3 2025 (reported 17 Nov 2025): revenue +47.5% to RMB998.4M, skincare +83.2% YoY to 49.2% of sales, operating loss margin halved to 8.4%, marking the third consecutive non-GAAP-profitable quarter per third-party recaps. Source: company Q3 2025 earnings release.
• Stock under pressure despite the turnaround: YSG is down ~25% in the past month and ~64% in the past six months even as fundamentals improved — implies the market is questioning durability of skincare growth or applying a broader China-ADR discount. Source: ChartMill price data.

Valuation Snapshot

At US$2.46 per ADS, market capitalization is approximately US$242M. Trailing-twelve-month earnings to 30 Sep 2025 were a US$66.5M loss, so the stock has no meaningful P/E; on FY2025 revenue (RMB4.30B ≈ US$604M at the 30 Sep 2025 RMB7.119/USD reference rate from the company's Q3 release), the implied enterprise-value-to-sales multiple is roughly 0.4× revenue, before netting out the ~US$148M of cash, restricted cash and short-term investments on the balance sheet at quarter-end. The market is effectively pricing Yatsen as a high-cash-burn-risk China consumer name in transition, not as a growing skincare platform; the bull case rests on skincare scaling further and non-GAAP profit converting to GAAP profit, while the bear case is that Perfect Diary's color-cosmetics base remains structurally flat in a competitive Chinese beauty market.

Risks And Watchpoints

• VIE structure and PRC regulatory exposure. A portion of revenue flows through the VIE (Huizhi Weimei); any PRC enforcement action against VIE arrangements, data-security rules (PIPL, CAC review), or cosmetics regulation (CSAR) could disrupt the model. The 2024 20-F flags this risk extensively.
• Skincare durability. Two-thirds of the FY2025 growth came from a single category (skincare brands +63.5% YoY). Investors should watch whether Galénic, DR.WU and Eve Lom sustain hero-product launches (Galénic No.3 VB Serum, DR.WU PDRN Serum) post Double 11.
• Marketing intensity vs. profitability. S&M was 68% of revenue in Q3 2025; the path to GAAP profit depends on holding that leverage as the company scales — any reversal during major shopping festivals could push the loss back out.
• Competition and consumer demand. Domestic rivals (Proya, Marubi, Winona) and global incumbents (L'Oréal, Estée Lauder) are pushing into China's mass-premium skincare segment; Chinese consumer demand for beauty remains uneven post-2024.
• Cash burn and runway. Cash plus short-term investments declined from RMB1.36B at YE2024 to RMB1.05B at YE2025, and operating cash flow was negative RMB126.8M in Q3 2025 alone — sustainability of the turnaround requires positive operating cash flow in 2026.
• Controlled-company / ADR-specific risks. Founder Jinfeng Huang controls super-voting Class B shares, ADS-ratio changes have already occurred (March 2024), and continued NYSE listing depends on PCAOB inspection access and avoidance of the HFCAA delisting mechanism.